FDA approves Rebyota, a first-in-class medication for the prevention of recurrent clostridium difficile infections

On November 30th, 2022 the US Food and drug administration granted the approval of Rebyota™ to Ferring pharmaceuticals. Rebyota™ is a first-in-class medication indicated for the prevention of recurrent Clostridium difficile infections (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI. Rebyota™ is a pre-packaged single-dose 150mL suspension fecal microbiota for rectal administration and it’s prepared from stool donated by qualified donors.  

Source https://ferringusa.com/?press=ferring-receives-u-s-fda-approval-for-rebyota-fecal-microbiota-live-jslm-a-novel-first-in-class-microbiota-based-live-biotherapeutic